Key Developments: Novo Nordisk A/S (NVO)

NVO on New York Consolidated

44.67USD
25 Nov 2014
Price Change (% chg)

$0.21 (+0.47%)
Prev Close
$44.46
Open
$44.46
Day's High
$44.78
Day's Low
$44.33
Volume
962,339
Avg. Vol
1,471,779
52-wk High
$49.10
52-wk Low
$34.30

Search Stocks

Latest Key Developments (Source: Significant Developments)

Novo Nordisk: Victoza receives positive opinion for use in adults with type 2 diabetes
Friday, 21 Nov 2014 08:29am EST 

Novo Nordisk A/S:Victoza receives positive Committee for Medicinal Products for Human Use opinion opinion for use in adults with type 2 diabetes and moderate renal impairment.Once the European Commission approves the label expansion, physician s in the European Union will be able to prescribe Victoza, the once-daily human glucagon-like peptide-1 (GLP-1) analogue, to adults with type 2 diabetes and moderate renal impairment without dose adjustments.  Full Article

Novo Nordisk says nine out of 10 patients lost weight with its obesity drug
Tuesday, 4 Nov 2014 01:00am EST 

Novo Nordisk A/S:Says new phase 3a data demonstrate that nine out of 10 adults with obesity lost weight with liraglutide 3 mg.Says clinical trial completers lost average of 9.2 pct.  Full Article

Novo Nordisk A/S invests DKK 750 million in new laboratories for diabetes research in Denmark
Thursday, 30 Oct 2014 08:00pm EDT 

Novo Nordisk A/S:Announced an investment of about 750 million Danish crowns (around $130 million) in new laboratories at the company's R&D campus in Maaloev, Denmark.Construction has started, and the new laboratory facility is expected to be ready for occupation in early 2016.  Full Article

Novo Nordisk A/S lowers high end of prior FY 2014 revenue outlook; reaffirms FY 2014 operating profit guidance; gives FY 2015 outlook
Thursday, 30 Oct 2014 02:38am EDT 

Novo Nordisk A/S:Expects FY 2014 sales growth measured in local currencies to be 7-9 pct.FY 2014 operating profit growth measured in local currencies is still expected at around 10 pct.Reported revenue of 83.572 billion Danish crowns and operating profit of 31.493 billion Danish crowns in FY 2013.Says that outlook for FY 2015 indicates high single-digit sales growth and around 10 pct. operating profit growth, both measured in local currencies.FY 2015 revenue of 98.100 billion Danish crowns and operating profit of 40.642 billion Danish crowns - Thomson Reuters I/B/E/S.  Full Article

Novo Nordisk gets U.S. subpoena related to Danish factory-Reuters
Friday, 24 Oct 2014 11:53am EDT 

Novo Nordisk A/S:Says has received a U.S. subpoena requesting documents regarding potential manufacturing issues at its giant Kalundborg facility in Denmark-Reuters.Says the request came from the office of the U.S. Attorney for the District of Massachusetts.Says the request is related to certain production units.Says Novo Nordisk is cooperating fully with the U.S. Attorney in this investigation but cannot determine or predict the outcome of this matter or assess the consequences thereof.Says cannot predict how long the investigation will take or when it will be able to provide additional information.  Full Article

Novo Nordisk A/S initiates share repurchase programme
Monday, 15 Sep 2014 09:18am EDT 

Novo Nordisk A/S:Initiates share repurchase programme.This programme is part of overall share repurchase programme of up to 15.0 bln Uses Danish Crown to be executed during 12-month period beginning Jan. 30.  Full Article

Novo Nordisk A/S says discontinues activities within inflammatory disorders
Tuesday, 2 Sep 2014 02:46am EDT 

Novo Nordisk A/S:Expects that all ongoing clinical activities within inflammatory disorders will be finalized within the coming six months.Expects as a consequence of the discontinuation of all research and development activities within inflammatory disorders to incur a non-recurring cost of around 700 million Danish crowns.Expects to provide an update of the financial guidance for FY 2014 in connection with the release of the financial results for the 9M of FY 2014 on Oct 30.  Full Article

Novo Nordisk A/S maintains FY 2014 outlook
Wednesday, 6 Aug 2014 08:00pm EDT 

Novo Nordisk A/S:Still expects FY 2014 sales growth measured in local currencies to be 7-10 pct.FY 2014 operating profit growth measured in local currencies is still expected at around 10 pct.FY 2013 revenue of 83.572 billion Danish crowns.FY 2013 operating profit of 31.493 billion Danish crowns.FY 2014 revenue estimate of 88.034 billion Danish crowns - Thomson Reuters I/B/E/S.FY 2014 operating profit estimate of 33.367 billion Danish crowns - Thomson Reuters I/B/E/S.  Full Article

Novo Nordisk A/S receives positive opinion on Xultophy (IDegLira) from European regulatory authorities
Friday, 25 Jul 2014 07:28am EDT 

Novo Nordisk A/S:Announced that Committee for Medicinal Products for Human Use (CHMP) under European Medicines Agency (EMA) adopted positive opinion, recommending marketing authorisation for Xultophy for treatment of type 2 diabetes mellitus in adults.Xultophy is intended brand name for IDegLira, first once-daily single injection combination of Tresiba(insulin degludec) and Victoza(liraglutide), developed for treatment of type 2 diabetes.CHMP positive opinion recommends that Xultophy will be indicated for treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with basal insulin do not provide adequate glycaemic control.  Full Article

Novo Nordisk A/S says FDA approves Novoseven RT for treatment of Glanzmann'S Thrombasthenia-Reuters
Monday, 7 Jul 2014 01:50pm EDT 

Novo Nordisk A/S:FDA approves Novoseven RT for the treatment of Glanzmann'S Thrombasthenia (GT) with refractoriness-Reuters.Novoseven RT also is approved in the European Union for the treatment of bleeding episodes in patients with GT.  Full Article

NORDIC STOCKS - Factors to watch on Nov 25

OSLO, Nov 25 - The following stocks may be affected by newspaper reports and other factors on Tuesday:

Search Stocks